Why I think $MBOT is the most undervalued, overlooked, multi-bagger around.
Microbot Medical's FDA-cleared LIBERTY robotic system is entering full market release in Q2 2026 with early hospital adoption, strong clinical data (100% navigation success, 92% radiation reduction), and multiple commercialization catalysts. The company targets a 2.5 million annual endovascular procedures market with a growing IP portfolio and secured capital runway.